Shares in SteadyMed (NSDQ:STDY) rose 6% today after the company said it inked a $30 million private placement with Adage Capital Management, OrbiMed, Deerfield Management and Kingon Capital Management.
The San Ramon, Calif.-based company plans to use its newly-acquired funds to prepare for the commercial launch of its pulmonary arterial hypertension treatment, Trevyent. The therapy is a combination of treprostinil and the PatchPump prefilled, disposable infusion system.
Get the full story at our sister site, Drug Delivery Business News.
The post SteadyMed raises $30m for Trevyent commercial launch appeared first on MassDevice.
from MassDevice http://ift.tt/2pLlTp1
Cap comentari:
Publica un comentari a l'entrada